Almonertinib Combined With Bevacizumab for EGFR-Mutant NSCLC Patients With Leptomeningeal Metastasis: A Prospective, Open-label, Multi-center, Single-arm Study
Latest Information Update: 25 Sep 2021
At a glance
- Drugs Aumolertinib (Primary) ; Bevacizumab (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms ATTRACT
- 07 Jul 2021 New trial record